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Abstract 
Tenascins are extracellular matrix glycoproteins associated with cell motility, proliferation 
and differentiation. Tenascin-C inhibits cell spreading by binding to fibronectin; tenascin-R and 
tenascin-X also have anti-adhesive properties in vitro. Here we have studied the adhesion 
modulating properties of the most recently characterized tenascin, tenascin-W. C2C12 cells, 
a murine myoblast cell line, will form broad lamellipodia with stress fibers and focal adhesion 
complexes after culture on fibronectin. In contrast, C2C12 cells cultured on tenascin-W fail 
to spread and form stress fibers or focal adhesion complexes, and instead acquire a multipolar 
shape with short, actin-tipped pseudopodia. The same stellate morphology is observed when 
C2C12 cells are cultured on a mixture of fibronectin and tenascin-W, or on fibronectin in the 
presence of soluble tenascin-W. Tenascin-W combined with fibronectin also inhibits the 
spreading of mouse embryo fibroblasts when compared with cells cultured on fibronectin 
alone. The similarity between the adhesion modulating effects of tenascin-W and tenascin-C 
in vitro led us to study the possibility of tenascin-W compensating for tenascin-C in tenas-
cin-C knockout mice, especially during epidermal wound healing. Dermal fibroblasts har-
vested from a tenascin-C knockout mouse express tenascin-W, but dermal fibroblasts taken 
from a wild type mouse do not. However, there is no upregulation of tenascin-W in the 
dermis of tenascin-C knockout mice, or in the granulation tissue of skin wounds in tenascin-C 
knockout animals. Similarly, tenascin-X is not upregulated in early wound granulation tissue in 
the tenascin-C knockout mice. Thus, tenascin-W is able to inhibit cell spreading in vitro and it 
is upregulated in dermal fibroblasts taken from the tenascin-C knockout mouse, but neither it 
nor tenascin-X are likely to compensate for missing tenascin-C during wound healing. 
Key words: tenascin, extracellular matrix, fibronectin, wound healing, C2C12. 
Introduction 
Tenascins  are  a  family  of  extracellular  matrix 
glycoproteins capable of influencing cell proliferation, 
fate and behavior by modifying cell adhesion either 
directly via their cell surface receptors or indirectly 
through interactions with other matrix molecules (1). 
The first member of the family to be characterized as 
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‘anti-adhesive’  was  tenascin-C.  Cells  cultured  on 
substrata coated with tenascin-C fail to spread, and 
cells  also  fail  to  spread  on  substrata  formed  from 
mixtures of tenascin-C and fibronectin, or on fibron-
ectin-coated  substrata  in  the  presence  of  soluble 
tenascin-C (2-7). The adhesion modulating properties 
of tenascin-R (8,9) and tenascin-X (10-12) are also well 
known. 
 Tenascin-W  is  the  most  recently  discovered 
member  of  the  tenascin  gene  family.  Its  expression 
during  development  is  largely  limited  to  smooth 
muscle, bone and the stroma of certain tumors (13-16). 
The addition of tenascin-W to the medium over oste-
oblasts  cultured  on  fibronectin  prevents  them  from 
spreading,  and  when  these  cells  are  cultured  on 
tenascin-W they remain rounded (15). Moreover, in 
transwell  assays  soluble  tenascin-W  promotes  the 
migration of tumor-derived cell lines (16) and osteo-
blasts  (17)  across  a  fibronectin-coated  filter.  These 
results suggest that tenascin-W may share some of the 
anti-adhesive properties of other tenascins.  
 The  tenascin-C  knockout  mouse  was  first  re-
ported to develop normally (18), but closer examina-
tion led to the identification of a number of develop-
mental abnormalities and well as abnormal responses 
to trauma (1). Tenascin-C is upregulated in the gran-
ulation  tissue  at  the  borders  of  skin  wounds  (19) 
where it is associated with the migration and prolif-
eration  of  myofibroblasts  and  epidermis.  However, 
skin wounds have been reported to heal normally in 
the  tenascin-C  knockout  mouse  (20).  We  therefore 
speculated that in these mice tenascin-W, if it has an-
ti-adhesive  properties,  might  compensate  for  tenas-
cin-C in healing wounds. 
 Here  we  have  cultured  C2C12  cells  on  tenas-
cin-W-coated substrata either alone or in combination 
with  fibronectin  and  show  that  tenascin-W  shares 
adhesion modulating properties with tenascin-C. We 
then show that tenascin-W is expressed by fibroblasts 
from the dermis of the tenascin-C knockout mouse, 
but  not  by  fibroblasts  derived  from  a  wild  type 
mouse. Finally, we examined the granulation tissue of 
healing  skin  wounds  in  the  tenascin-C  knockout 
mouse for upregulation of tenascin-W. 
Materials and methods 
Proteins  and  antibodies.  Fibronectin  was  iso-
lated  from  medium  conditioned  by  primary  mouse 
embryonic  skin fibroblasts. Medium (approximately 
700 ml) from confluent 4th passage cultures was col-
lected and concentrated 30 fold by precipitation with 
ammonium  sulfate.  The  concentrated  conditioned 
medium was dialyzed against Ca++/Mg++-free phos-
phate buffered saline (PBS) and applied to a 10 ml 
gelatin-Sepharose  (Amersham/GE  Health  Care) 
column. The column was washed with 0.5 M urea in 
PBS, and fibronectin was eluted with 4M urea in PBS. 
The  purified  protein  was  dialyzed  against  PBS  and 
sterilized  by  filtration  through  a  0.2  m  pore  filter. 
Full  length  mouse  recombinant  tenascin-W  was 
cloned,  expressed  and  purified  as  described  in 
Scherberich et al. (13). The rat anti-mouse tenascin-C 
monoclonal antibody (MTn-12) was characterized by 
Aufderheide and Ekblom (21), the rabbit polyclonal 
anti-mouse  tenascin-W  was  characterized  by  Scher-
berich et al. (13), and the anti-tenascin-X rabbit poly-
clonal antibody was characterized by Matsumoto et 
al. (22). The mouse anti-vinculin monoclonal antibody 
was purchased from Sigma. 
Substrata and cell culture. Tissue culture plastic 
dishes were coated with mouse fibronectin (5 g/ml) 
or  recombinant  mouse  tenascin-W  (5  g/ml  or  10 
g/ml)  diluted  in  serum-free  Dulbecco’s  Modified 
Eagle’s  Medium  (DMEM)  for  90  min,  rinsed  in 
DMEM,  blocked  for  15  min  with  1  mg/ml 
heat-inactivated  bovine  serum  albumin  (BSA),  and 
rinsed 3X in DMEM. Control dishes were incubated in 
DMEM without proteins and then rinsed and blocked 
as described. C2C12 cells (23) (a gift from Dr. Zach 
Hall, National Institute of Neurological Disorders and 
Stroke, National Institutes of Health, Bethesda, MD) 
or mouse embryo fibroblasts (see below) were washed 
in DMEM with 10% fetal calf serum (FCS), rinsed in 
DMEM  without  serum,  and  a  250  l  aliquot  was 
added  to  the  coated  substratum  and  the  cells  were 
incubated at 37oC. After 90 min tenascin-W diluted in 
warm DMEM was added to the medium of some of 
the cells being cultured on fibronectin-coated dishes 
(to a final concentration of 5 or 10 g/ml); a similar 
amount of warm DMEM alone was added to the other 
cultures at this time as a control. After at total of 2 hr 
in culture the cells  were fixed in 1% paraformalde-
hyde in DMEM for 30 min, then rinsed 3X in PBS and 
processed for immunocytochemistry. All experiments 
were conducted in triplicate. 
Immunocytochemistry,  photography  and  im-
age analysis. After fixation and rinsing the cells were 
blocked overnight in PBS with 0.5% BSA at 4oC, per-
meabilized with 0.1% Triton X-100 for 5 min, and in-
cubated  in  anti-vinculin  (see  above)  and/or 
TRITC-labeled phalloidin (Sigma) for 1 hr. The cells 
were  then  rinsed  and  incubated  in  secondary  anti-
body (Alexa 488-labeled goat anti-mouse; Invitrogen) 
for 45 min. Finally, the cells were rinsed in PBS con-
taining  DAPI  (Sigma),  rinsed  and  coverslipped.  To 
measure cell areas, images of cells labeled with phal-
loidin were converted to high contrast, grayscale im-




analyzed using Adobe Photoshop CS3 and converted 
to cell area by similarly analyzing a black square of a 
known size. Statistical differences (p < 0.05) were de-
termined using a two-tailed t-test. 
Fibroblast  cultures  and  immunoblotting.  Pri-
mary embryonic skin fibroblasts were isolated from 
129/Sv  mouse  wildtype  and  TN-C  knockout  (20) 
embryos  at  embryonic  day  15.5.  The  dissected  skin 
was  rinsed  in  Ca++/Mg++-free  PBS,  minced  and  di-
gested  in  5  ml  0.05%  trypsin-EDTA  (Gib-
co/Invitrogen) for 45 min at 37°C. The digestion was 
stopped by adding the same volume of DMEM con-
taining 10% FCS. Large debris was removed by cen-
trifugation  and  cells  were  collected.  Primary  fibro-
blasts were plated in 10 cm dishes (Falcon) in 10 ml 
DMEM/10%  FCS  and  grown  to  confluency.  Cells 
were passaged once a week and spontaneously im-
mortalized as described in Brellier et al. (24). To study 
tenascin  expression,  conditioned  medium  was  col-
lected, separated by SDS-PAGE, transferred and im-
munostained  as  described  previously  (12).  Equal 
loading and transfer was confirmed with amido black. 
The  intensities  of  the  immunostained  bands  were 
measured with ImageQuant TL (v2005). Each tenascin 
value then was normalized to the intensity of an an-
ti-vinculin immunostained band.  
Wound  healing  and  immunohistochemistry. 
Handling  of  the  animals  before  and  during  the  ex-
periments,  as  well  as  the  experiments  themselves, 
were approved and supervised by the Swiss Agency 
for the Environment, Forests and Landscape and the 
Veterinary Service of the Canton of Bern. In addition 
we followed the guidelines of INSERM and the Fed-
eration of Laboratory Animal Science Associations. To 
study  wound  healing  in  mice  we  adapted  an  inci-
sional tail wound model based on a previous study 
(25). For immunoblot analysis the tail tips of 3 SL-129 
mice were cut generating 5mm long fragments that 
were used as controls. These were compared with 5 
mm long tail fragments from tenascin-C+/+ or tenas-
cin-C-/- SL-129 mice that contained wounds that were 
allowed  to  heal  for  1  day,  3  days  or  10  days.  All 
fragments were cut into small pieces with a scalpel 
and homogenized with a mortar and pestle in 400 µl 
of RIPA buffer. After 2 min of mixing, the solutions 
were  centrifuged  to  remove  debris.  Samples  were 
boiled in Laemmli sample buffer and stored at -20°C. 
For  immunohistochemical  analysis,  wounded  tail 
fragments like those described above were collected 
from tenascin-C+/+ mice (2 male, 1 female, aged 3-7 
weeks) and from tenascin-C-/- mice (2 male, 1 female, 
aged 5 weeks) and fixed overnight in 4% paraform-
aldehyde in PBS. The tissues were then rinsed, incu-
bated  overnight  at  4oC  in  20%  sucrose  in  PBS,  and 
embedded  in  O.C.T.  (Sakura).  Frozen  sections  were 
collected  on  presubbed  slides  (Fisher).  Dried  slides 
were then rinsed, blocked in PBS with 0.5% BSA, and 
incubated overnight in MTn-12 (anti-tenascin-C), an-
ti-tenascin-X and anti-mouse tenascin-W (see above). 
The next day the slides were rinsed, blocked and then 
incubated for 2 hr in a mixture of diluted Alexa 488 
labeled-goat  anti-rat  secondary  antibody  and  Alexa 
594  labeled-goat  anti-rabbit  secondary  antibody 
(Invitrogen).  Slides  were  rinsed  in  PBS  with  DAPI, 
then rinsed, coverslipped and photographed. 
Results and discussion 
The mouse myoblast cell line C2C12 has the po-
tential to transdifferentiate into osteoblasts, a cell type 
that  we  have  previously  shown  can  bind  to  tenas-
cin-W (13, 17). We selected C2C12 cells for this study 
because  we  found  that  these  cells  adhere  to  tenas-
cin-W, yet they do not express tenascin-W in the ab-
sence of BMP2 (13) and they were used in an earlier 
study  illustrating  the  anti-adhesive  properties  of 
tenascin-C  (5).  C2C12  cells  cultured  for  2  hr  in  the 
absence  of  serum  on  tissue  culture  plastic  blocked 
with  BSA  will  attach  and  spread,  resulting  in  mor-
phologically diverse multipolar cells with many small 
lamellae  and  short  phalloidin-labeled  stress  fibers 
(Fig. 1A). In contrast, when these cells are cultured for 
2 hr on tissue culture plastic coated with 5 g/ml (~25 
nM)  of  mouse  fibronectin  blocked  with  BSA  they 
spread and form large lamellae as well as stress fibers 
ending  in  anti-vinculin  labeled  focal  adhesion  com-
plexes (Fig. 1B). When cultured on 10 g/ml (~50 nM) 
mouse tenascin-W blocked with BSA the C2C12 cells 
fail  to  spread  and  form  lamellae.  Instead,  cells  on 
tenascin-W are typically triangular or polygonal and 
have numerous small, actin-rich processes (Fig. 1C). 
Stress fibers are not seen, and the anti-vinculin stains 
the cytoplasm of these cells instead of the focal adhe-
sion  complexes  seen  when  cells  are  cultured  on  fi-
bronectin. On mixed fibronectin/tenascin-W substra-
ta an intermediate morphology is usually observed: 
the C2C12 cells do not form large lamellae, but a few 
anti-vinculin-positive  focal  adhesion  complexes  are 
typically  present  (Fig.  1D).  There  were  statistically 
fewer  (p  <  0.001)  anti-vinculin-positive  focal  adhe-
sions in C2C12 cells cultured on mixed substrata (8.5 ± 
9.2, n = 11) than on fibronectin alone (26.7 ± 14.5, n = 
10).  The  adhesion  modulating  effects  of  substra-
tum-bound tenascin-W were also observed with sol-
uble tenascin-W. When C2C12 cells were first allowed 
to attach and spread on fibronectin-coated substrata 
for  90  min  and  tenascin-W  was  then  added  to  the 
medium for an additional 30 min prior to fixation and 




morphology and short actin-rich processes that were 
also observed with cells cultured on tenascin-W alone 
(Fig. 1E). 
 The different morphologies of C2C12 cells fol-
lowing culture on fibronectin, tenascin-W, mixtures of 
fibronectin and tenascin-W, and on fibronectin with 
soluble tenascin-W, are identical to the morphologies 
we  previously  described  for  C2C12  cells  cultured 
under  similar  conditions  on  tenascin-C  and  fibron-
ectin  (5).  In  our  previous  study  we  observed  stress 
fibers developing in C2C12 cells 90 min after culture 
on tissue culture plastic coated with 50 nM fibronectin 
(about twice the concentration we used here), while 
cells cultured on tissue culture plastic coated with 50 
nM  tenascin-C  are  polygonal  with  short,  actin-rich 
processes  indistinguishable  from  cells  cultured  on 
tenascin-W.  One  potentially  important  difference 
between our previous study and the current one has 
to do with the species of origin of the fibronectin and 
tenascin:  Fischer  et  al.  (5)  used  fibronectin  purified 
from  horse  serum  and  recombinant  chicken  tenas-
cin-C,  but  here  we  used  mouse  fibronectin  and  re-
combinant mouse tenascin-W. This seemed appropri-
ate,  as  there  may  be  a  functional  integrin-binding 
RGD motif found in the second fibronectin type III 
domain of mouse tenascin-W (13) that is missing in 
avian (and human) tenascin-W (26).  
 
 
Fig. 1. C2C12 cells cultured on tissue culture plastic (A), fibronectin (B), tenascin-W (C), a mixture of fibronectin and tenascin-W (D) or 
on fibronectin with tenascin-W added to the medium (E). After 2 hr the cells were fixed and stained with TRITC-labeled phalloidin (red) 
to show polymerized actin, anti-vinculin (green) to show focal adhesion complexes, and the nuclear marker DAPI (blue). C2C12 cells 
spread and form stress fibers and numerous focal adhesion complexes on fibronectin, but are polygonal on tenascin-W and have nu-
merous short, actin-rich processes. Cells cultured on mixtures of fibronectin and tenascin-W, or on fibronectin with tenascin-W in the 
medium, resemble cells cultured on tenascin-W alone. Total areas of cells cultured under the conditions indicated were measured and 
compared (sample size and standard deviations are indicated; F, G). C2C12 cells are significantly more spread on 5 g/ml fibronectin than 
on tissue culture plastic, and are significantly less spread on 10 g/ml tenascin-W than on tissue culture plastic alone. The C2C12 cells are 
also significantly less spread on the mixture of tenascin-W and fibronectin than on fibronectin alone, and on fibronectin with 10 g/ml 





Fig. 2. Mouse embryo fibroblasts cultured on fibronectin (A) or combinations of fibronectin and tenascin-W (B) or fibronectin and 
tenascin-C (C) stained with TRITC-labeled phalloidin (red) and DAPI (blue). Mouse embryo fibroblasts cultured for 2 hr on fibronectin 
spread and form stress fibers; mouse embryo fibroblasts cultured on fibronectin mixed with tenascin-W or tenascin-C are stellate and fail 
to form lamellipodia or stress fibers. When the total cell area is measured, there is a significant decrease in the area of cells cultured on 
the mixed substrata when compared with fibronectin alone (D). Sample size and standard deviations are indicated. Scale bar = 100 m. 
 
 
 C2C12 cells cultured on mixed fibronectin and 
tenascin-W  substrata  have  fewer  an-
ti-vinculin-positive  focal  adhesion  complexes  than 
cells cultured on fibronectin alone, and after the addi-
tion  of  tenascin-W  to  the  medium  C2C12  cells  cul-
tured  on  fibronectin  fail  to  elaborate  lamellae  and 
stress fibers. To quantify the effects of tenascin-W on 
cell morphology and to determine the effects of dif-
ferent concentrations of tenascin-W, the total area of 
C2C12  cells  under  different  culture  conditions  was 
measured  and  compared  (Fig.  1F,  G).  As  expected, 
cells cultured on tissue culture plastic coated with 5 
g/ml fibronectin are more spread than cells cultured 
on tissue culture plastic alone. No effect on cell area 
was  observed  when  C2C12  cells  were  cultured  on 
dishes  coated  with  5  g/ml  tenascin-W,  but  on  10 
g/ml of tenascin-W the cell area is significantly less 
than  the  area  of  cells  cultured  on  fibronectin  or  on 
tissue culture plastic alone. Cells cultured on mixed 
fibronectin/tenascin-W substrata are less spread than 
cells  cultured  on  fibronectin  alone,  as  are  cells  cul-
tured on fibronectin with 10 g/ml tenascin-W in the 
medium. These results show that tenascin-W has the 
same effects on C2C12 cell morphology as tenascin-C, 
and that tenascin-W shares the adhesion modulating 
activity of tenascin-C when cells are cultured on fi-
bronectin. The effects of tenascin-W on cell spreading 
are not limited to C2C12 cells. When mouse embryo 
fibroblasts are cultured on 5 g/ml fibronectin they 
spread  and  form  an  extensive  array  of  stress  fibers 
(Fig. 2A). In contrast, mouse embryo fibroblasts cul-
tured on a combination of fibronectin and tenascin-W 
fail to spread and form stress fibers, and instead ac-
quire the multipolar morphology described above for 
C2C12 cells cultured on tenascin-W (Fig. 2B). A simi-
lar  morphology  is  seen  when  mouse  embryo  fibro-
blasts  are  cultured  on  combinations  of  5  g/ml  fi-
bronectin and 10 g/ml of tenascin-C (Fig. 2C). When 
the areas of mouse embryo fibroblasts cultured under 
these  conditions  are  measured  and  compared,  they 
are  significantly  (p  <  0.001)  less  on  the  mixed  sub-
strata containing tenascin-W and tenascin-C than on 
fibronectin alone (Fig. 2D). 
 Tenascin-C  is  typically  expressed  by  cultured 
dermal fibroblasts (27) and is upregulated in granula-
tion tissue at the margins of healing skin wounds (19). 
To determine if tenascin-W may be able to compen-
sate for the tenascin-C missing from the granulation 
tissue  of  tenascin-C  knockout  mice,  primary  fibro-




tenascin-C  -/-  mice  were  examined  for  tenascin-W 
expression  by  immunoblotting.  Tenascin-W  expres-
sion  was  observed  in  the  cells  from  the  dermis  of 
tenascin-C  -/- mice, but not in the control cells (Fig. 
3A). The acquisition of tenascin-W expression came 
over  time,  with  repeated  passages  (Fig.  3B).  This 
suggests that at least some cells that normally express 
tenascin-C are able to upregulate tenascin-W follow-
ing knockout of tenascin-C. To determine if a similar 
upregulation takes place in vivo during the healing of 
skin  wounds,  fragments  of  epidermis  and  dermis 
from  unwounded  tails  and  epidermis,  dermis  and 
early granulation tissue from wounds that had healed 
for 1-10 days were homogenized and studied for the 
expression  of  tenascin-C  and  tenascin-W  by  im-
munoblot  analysis  (Fig.  3C).  Tenascin-C  is  upregu-
lated 2.7 fold 3 days after wounding and 4.5 fold 10 
days after wounding. There is no difference between 
tenascin-W  expression  in  wounds  of  tenascin-C  +/+ 
versus tenascin-C -/- mice with a slight upreguation of 
tenascin-W after 2 days (average 1.5 fold) and no up-
regulation  10  days  after  wounding.  This  was  con-
firmed by examining frozen sections through wounds 
in the tails of tenascin-C +/+ and tenascin-C -/- mice 3 
days  following  injury  with  anti-tenascin-C  and  an-
ti-tenascin-W. As reported previously (19), tenascin-C 
is  abundant  in  the  early  granulation  tissue  of  the 
healing wounds (Fig. 4A). In contrast, tenascin-W is 
found  in  patches  in  the  normal  skin  near  the  der-
mal/epidermal junction in regions corresponding to 
the  connective  tissue  septae  that  run  from  the  epi-
dermis to deep connective tissue (the ‘wrinkles’ in the 
tail), but it is not present in the early granulation tis-
sue (Fig. 4A). In the healing cutaneous wounds in the 
tail  of  the  tenascin-C  knockout  mice,  no  tenascin-C 
immunoreactivity  was  seen,  and  the  distribution  of 
tenascin-W was identical to that seen in the control 
dermis (Fig. 4B). Therefore, even though tenascin-W 
shares the adhesion modulating properties of tenas-
cin-C in vitro, and it can be upregulated in fibroblasts 
derived from the dermis of tenascin-C-/- mice, it is not 
upregulated during wound healing in the skin of the 
tenascin-C knockout mice and is unlikely to be com-
pensating for the missing tenascin-C in this system. 
The  observation  made  by  others  (20)  that  levels  of 
fibronectin  appear  to  be  lower  in  the  wounds  of 
tenascin-C-/-  mice  may  offer  an  explanation  for  the 
apparently normal phenotype. Moreover, tenascin-X 
has  well  documented  anti-adhesive  properties  (12) 
and may play a role in compensating for the missing 
tenascin-C. However, antibodies to tenascin-X reveal 
the previously described pattern of expression in the 
epidermis and deep dermis (22) in sections of healing 
wounds from control mice (Fig. 4C), but do not show 
upregulation  in  the  early  granulation  tissue  of 
wounds in the tenascin-C -/- mice (Fig. 4D).   
 
 
Fig. 3. The expression of tenascin-C (TNC) and tenascin-W (TNW) by primary fibroblasts from tenascin-C+/+ and tenascin-C-/- dermis 
were compared by immunoblotting (A). Fibroblasts from normal dermis express tenascin-C, but fibroblasts derived from tenascin-C 
knockout skin expresses tenascin-W. Amido black was used to demonstrate equal loading (not shown). The expression of tenascin-W by 
the fibroblasts derived from tenascin-C-/- dermis increased with passaging (B). The expression of tenascins-C and -W was also examined 
by immunoblotting homogenates of control and wounded skin (C). There is an increase in the expression of tenascin-C 3 (2.7 fold) and 10 
days (4.5 fold) following wounding. Tenascin-W expression is upregulated 1.5 fold 3 days following wounding, but is not upregulated after 
10 days both in tenascin-C +/+ and tenascin-C -/- mice. Anti-vinculin (VN) was used to normalize the changes in the intensity of the 
anti-tenascins. In wounds from the tenascin-C-/- mice, the expression of tenascin-W remains unchanged. Apparent molecular weights are 
indicated by size standards (kDa).  





Fig. 4. Tenascin-C and tenascin-W expression in healing wounds was confirmed by immunohistochemistry (A, B). Three days following 
an incision in the skin of a tenascin-C+/+ mouse tail, anti-tenascin-C (green) stains the early granulation tissue (gt) adjacent to the wound 
(A). Anti-tenascin-W (red) stains patches at the border of the epidermis (ep) and dermis (d; arrow); patchy staining was seen both near 
and far from the scab (s) and appears to coincide with the fibrous septum than runs from the epidermis to deeper connective tissue. In an 
unwounded tail, tenascin-C immunoreactivity is limited to the dermal-epidermal junction and the capsule around hair follicles (hf; inset). 
In a similar wound in the skin of a tenascin-C-/- mouse the anti-tenascin-W staining is unchanged (B). The expression of tenascin-X (red) 
in the tail wounds was also studied by immunohistochemistry (C, D). Tenascin-X is found in the epidermis (e), deep dermis and in 
structures associated with the hair follicles (hf), but it is not upregulated in the early granulation tissue (gt) of wild type or tenascin-C 
knockout mouse wounds. Scale bar = 100m. 
 
 
Our  results  show  that  tenascin-W  shares  the 
adhesion modulating properties of other members of 
the tenascin gene family. The molecular mechanisms 
underlying these properties remain unknown. Future 
studies  should  be  directed  to  determining  if  tenas-
cin-W can bind to fibronectin, and if it does, if it binds 
to the same region as tenascin-C. In addition, putative 
integrin  binding  domains  have  been  identified  in 
tenascin-W,  and  the  integrins  that  recognize  these 
sites and the signaling pathways mediated by these 
integrins need to be identified. Initial studies point to 
a conserved KGD motif playing a role in regulating 
the anti-adhesive properties of tenascin-W (17) and 8 
integrins promoting tenascin-W mediated motility, at 
least in tenascin-W from mouse (14).  
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